

1 **Neutrophils form extracellular traps in response to *Opisthorchis viverrini* crude antigens and**  
2 **these traps are elevated in neutrophils from opisthorchiasis patients with hepatobiliary**  
3 **abnormalities**

4

5 Running title: NETs in response to *Ov* crude antigens

6

7 Watakulsin K<sup>1</sup>, Chuenchom C<sup>1</sup>, Donsa W<sup>2</sup>, Thapphan C<sup>1,4</sup>, Tran Duong T<sup>1,4</sup>, Chareonsudjai S<sup>1,4</sup>,  
8 Faksri K<sup>1,4</sup>, Suttiprapa S<sup>2</sup>, Tangkawatana, S<sup>2</sup>, Sripa B<sup>2</sup>, Edwards S W<sup>3</sup> and Salao K<sup>1,4#</sup>

9

10 <sup>1</sup>Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

11 <sup>2</sup>WHO Collaborating Centre for Research and Control of Opisthorchiasis (Southeast Asian Liver  
12 Fluke Disease), Tropical Disease Research Center, Faculty of Medicine, Khon Kaen University,  
13 Khon Kaen, Thailand

14 <sup>3</sup>Institute of Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool,  
15 Liverpool, UK

16 <sup>4</sup>Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen  
17 University, Khon Kaen, Thailand

18

19 #Corresponding author: Asst/Prof. Kanin Salao, Email: [kaninsa@kku.ac.th](mailto:kaninsa@kku.ac.th)

20 **Abstract**

21 *Opisthorchis viverrini* (*Ov*) infection can cause several disease conditions of the bile duct  
22 including hepatobiliary abnormalities (HBAs) and the most severe, cholangiocarcinoma (CCA).  
23 Fibrosis occurs when tissues are damaged and normal wound-healing responses are dysregulated.  
24 Neutrophils are the first cells to migrate to an infection site to protect the host from intruding  
25 extracellular pathogens through a wide range of effector mechanisms such as phagocytosis,  
26 production of reactive oxygen species, proteases, or release of neutrophil extracellular traps  
27 (NETs). In this work, we used confocal microscopy to assess whether *Ov* crude antigens can cause  
28 release of NETs from neutrophils from *Ov*-free individuals. We demonstrated for the first time  
29 that these antigens could induce release of NETs *ex-vivo* in a dose-dependent manner from  
30 neutrophils isolated from *Ov*-free individuals. Intriguingly, when we measured NETs from  
31 neutrophils isolated from *Ov*-infected patients, we found increased spontaneous production of  
32 NETs in patients with HBAs. Interestingly, exposure to *Ov* crude antigens lowered the level of  
33 NETs released by neutrophils from patients with active *Ov* infection regardless of HBA status. We  
34 propose that in the case of acute *Ov* infection, even when concentration of *Ov* antigens is relatively  
35 low, neutrophils can form NETs. However, when this infection becomes chronic, manifesting as a  
36 definite HBA, the levels of NET production are reduced when treated with *Ov* crude antigens.  
37 Excessive production of proinflammatory mediators from these NETs might have effects on the  
38 parasites, but may also lead to excessive injury of surrounding tissues resulting in HBAs and may  
39 lead eventually to the most severe complications such as CCA.

40

41 *Word Count: 257*

42 **Keywords:** Neutrophils extracellular traps, *Opisthorchis viverrini*, neutrophils, Hepatobiliary abnormality

## 43 **Introduction**

44 Infection with *Opisthorchis viverrini* (*Ov*) or liver fluke is endemic in the Lower Mekong regions  
45 of Southeast Asia, including Thailand, with approximately 8 million people infected, especially in  
46 the northeast of Thailand where consumption of raw freshwater fishes is common (Sripa et al.,  
47 2011). The life cycle of *Ov* requires three different hosts (Smout et al., 2011). First an aquatic snail  
48 (first intermediate host) ingests *Ov* eggs from contaminated feces. Asexual reproduction of the  
49 parasite produces numerous cercariae which escape from the snail and penetrate freshwater fish  
50 (second intermediate host) (Smout et al., 2011). The cercariae then encyst as metacercariae that  
51 are infective to the final definitive hosts including humans. The metacercariae excyst in the  
52 duodenum and migrate into the intrahepatic bile ducts to mature (Smout et al., 2011). Infection  
53 can cause several disease conditions of the bile duct including cholangitis, cholelithiasis,  
54 hepatobiliary abnormalities (HBAs) and the most severe complication, cholangiocarcinoma  
55 (CCA) (Elkins et al., 1996, Mairiang et al., 2006, Mairiang et al., 1992, Mairiang and Mairiang,  
56 2003, Sripa et al., 2007). HBAs occur when tissues are damaged and normal wound-healing  
57 responses are dysregulated (Wynn and Ramalingam, 2012), usually as a result of repetitive tissue  
58 injury (Borthwick et al., 2013) such as may be caused by *Ov* infection (Mairiang and Mairiang,  
59 2003). To date, it is proposed that that tissue damage caused by *Ov* can be due to 1) physical  
60 damage, 2) release of reactive oxygen species (ROS) released from neutrophils, 3) inflammation  
61 (Sripa et al., 2012). However, evidence to support the last of these is scarce or even contradictory.

62

63 Neutrophils are the first cells to migrate to an infection site to protect the host from intruding  
64 extracellular pathogens. Our group recently reported that functions of neutrophils were enhanced  
65 in patients infected with the liver fluke (*Ov*) and that this increased function was associated with

66 HBAs (Salao et al., 2020), suggesting a double-edged sword role of neutrophils in the liver fluke.  
67 Neutrophils act via a wide range of effector mechanisms such as phagocytosis, production of  
68 reactive oxygen species, and release of proteases and of neutrophil extracellular traps  
69 (NETs)(Nathan, 2006). It was initially thought that NETs are responsible mostly for attacking  
70 bacterial infections, especially those in which bacterial biofilms are formed (Khamwong et al.,  
71 2022, Thanabalasuriar et al., 2019). Their role in helminth infections is poorly known. NETs  
72 consist of decondensed chromatin released from neutrophils together with granular proteins and  
73 histones. NETs can be classified into two types namely suicidal and vital NETs. Conventional  
74 suicidal NETs are formed after cell death (Fuchs et al., 2007), whilst vital NETs are formed while  
75 neutrophils are still alive (Fuchs et al., 2007). Compelling evidence demonstrates that NETs are  
76 released in response to various parasites and cause pathogenesis such as in malaria (Babatunde  
77 and Adenuga, 2022, Knackstedt et al., 2019). However, there has been no study of NETs in *Ov*  
78 infection with associated HBAs.

79

80 In this work, we used confocal microscopy to assess whether *Ov* crude antigens can cause NET  
81 release from neutrophils from *Ov*-free individuals. We then asked whether NETs are incorporated  
82 with the granule proteins myeloperoxidase (MPO) and neutrophil elastase (NE). In addition, we  
83 measured NET release from human neutrophils after challenge with *Ov* crude antigens *ex vivo*  
84 from *Ov*-infected patients with or without HBAs.

85

## 86 **Materials and methods**

87 *Participants*

88 For NET measurement by confocal microscopy, three *Ov*-free individuals without HBAs who were  
89 regular blood donors were recruited from Blood Bank in Srinagarind University Hospital. These  
90 individuals donated blood from which neutrophils were obtained.

91 For NET measurement by spectro cytometry, *Ov*-infected patients were from ten villages in  
92 Kalasin Province (Thailand). Individuals aged between 20 and 60 years were recruited into this  
93 study. They were separated into two groups: *Ov*-positive patients without HBAs (*Ov*<sup>+</sup>HBA<sup>-</sup>) and  
94 *Ov*-positive patients with HBAs (*Ov*<sup>+</sup>HBA<sup>+</sup>). Written informed consent was obtained from each  
95 participant. This study complied with the standard good clinical practice (GCP) guidelines and  
96 was approved by the Ethics Committee of Khon Kaen University, Khon Kaen, Thailand, reference  
97 numbers HE591185 and HE480528.

#### 98 *Sample-size calculation*

99 A statistical power analysis was performed to calculate required sample size. With an alpha  
100 = 0.05 and power = 0.80, the projected sample size for this effect size (G\*Power 3.1.9.2 analysis)  
101 was approximately 3 per group.

102

#### 103 *Ultrasonography*

104 A detailed description of the ultrasonography methods used in this study can be found in previous  
105 publications (Mairiang et al., 2012, Sripa et al., 2009). Using a mobile, high-resolution ultrasound  
106 (US) machine (GE model LOGIQ Book XP, GE healthcare, WI, USA), hepatobiliary  
107 abnormalities including portal-vein radical echoes, echoes in liver parenchyma, indistinct  
108 gallbladder wall, gallbladder size, sludge and suspected CCA, were graded and recorded.  
109 Individuals were classified as not having hepatobiliary abnormalities (“HBA-”) if the US grade  
110 was 0 or 1, or as having abnormalities (“HBA+”) if the US grade was 2 or 3. Individuals with

111 alcoholic liver disease, which is seen as fatty liver by US examination, were excluded. Individuals  
112 with marked hepatic fibrosis not related to *Ov* infection (e.g., cirrhosis due to hepatitis C and B  
113 virus) were also excluded from this study. Our assumption was that remaining types of HBAs in  
114 *Ov*-infected individuals were due to chronic *Ov* infection.

115

#### 116 *Preparation of Ov crude antigens*

117 Adult *Ov* worms from experimentally infected hamsters (previously described (Wonkchalee et al.,  
118 2012)) were washed three times with sterile phosphate-buffered saline (PBS pH 7.2) containing  
119 0.149 M sodium chloride (Fisher Scientific, NJ), 8.29 mM disodium hydrogen phosphate (Acros  
120 Organics, NJ) and 18 mM sodium dihydrogen phosphate monohydrate (Fisher Scientific, NJ) in  
121 deionized (DI) water. A 100x Protease Inhibitor Cocktail (Calbiochem, CA) was added, the  
122 mixture (including worms) homogenized using an ultrasonic (MISONIC Sonicator 3000, US) and  
123 then centrifuged at 4 °C, 15,000 g for 30 min. The BCA™ Protein Assay Kit (PIERCE, IL) was  
124 used to determine the protein yield of *Ov* crude antigens in the supernatant, which was collected  
125 and stored at -80 °C until used.

126

#### 127 *Neutrophil isolation*

128 Blood was collected from all participants in sodium heparin spray coated tubes (cat# 367874,  
129 Becton Drive, NJ). Whole blood was mixed with HetaSep™ (cat # 07906, Stem Cell Technologies  
130 Inc.) at a ratio of 1:5 and was incubated at 37 °C for 30 min until the buffy coat interphase formed  
131 approximately 50% of total volume. Neutrophils were isolated from the buffy coat by using Ficoll-  
132 Hypaque (cat# 25-072-CV, Corning), at a ratio of 1:1 and centrifuged at 500 g continuously for 30

133 min. The granulocyte layer in the bottom was carefully removed and added to RPMI 1640 media  
134 (cat# 31800105, Gibco) followed by lysis buffer at a ratio 1:9 to remove erythrocytes, then  
135 centrifuged at 500 x g for 3 min. The supernatant was discarded, and cells were resuspended in  
136 media at a final concentration  $1 \times 10^6$  cells/mL.

137

### 138 *NET measurement by confocal microscopy*

139 Neutrophils (approximately  $2 \times 10^5$  cells/mL) from *Ov*-free donors (approximately  $2 \times 10^5$  cells/mL)  
140 were seeded onto sterile round coverslips in 24-well plates. *Ov* crude antigens at various final  
141 concentrations (2, 5, 10, 15 and 20  $\mu\text{g}$  protein/mL), or a positive control PMA (cat# P1585, Sigma)  
142 at 1 mg/mL), were added to the 24-well plates and incubated at 37 °C for 3 h to allow for NET  
143 formation. Cells adhering to the coverslips were fixed with 4% paraformaldehyde and kept  
144 overnight. Cells were washed with 1X Tris-buffered saline (TBS) three times for 5 min each. Cells  
145 were permeabilized using 0.05% Tween 20 in TBS for 1 min then blocked using 2% bovine serum  
146 albumin (BSA) for 30 min and washed three times with 1X TBS. Primary antibody, anti-elastase  
147 antibody (cat# AB21590, Abcam), and anti-myeloperoxidase antibody (cat# AB109116, Abcam),  
148 were diluted (1:200) in blocking buffer then incubated for 1 h. Cells were washed three times for  
149 5 min with 1X TBS. Secondary antibody, goat anti-mouse IgG H&L (Alexa Fluor 488, cat#  
150 AB150113, Abcam), and donkey anti-rabbit IgG H&L (Alexa Fluor 647, cat# AB150075, Abcam)  
151 were diluted (1:400) in blocking buffer then incubated for 1 h and washed further 3 times for 5  
152 min with 1X TBS. Cells were stained with DAPI (cat# A1001, Biochemica), which was diluted  
153 (1:10000) in TBS for 3 min. Cells were washed twice with 1X TBS and mounted using 70%  
154 glycerol. Cells were then imaged on a confocal laser scanning microscope (Zen 2.1 software, Zeiss

155 LSM800) using 10X and 63X objectives. To quantify the amount of NETs, an average nuclear  
156 area of neutrophils ( $\mu\text{m}^2/\text{cell}$ ) was calculated using ImageJ software by the following equation:

157

$$158 \quad \text{Average nuclear area } (\mu\text{m}^2/\text{cell}) = \frac{\text{Total area of nuclei}}{\text{Total number of cells}}$$

159

#### 160 *NET measurement by spectro cytometry*

161 Neutrophils (approximately  $2 \times 10^5$  cells/mL) from *Ov*-infected patients were seeded into 96-well  
162 plates (Thermo Fisher Scientific). *Ov* crude antigens at various concentrations (10  $\mu\text{g}/\text{mL}$ ) were  
163 added to the 96-well plates and the plates incubated at 37 °C for a further 3 h.  $\text{CaCl}_2$  (0.1 M) was  
164 then added to stop reactions followed by addition of 50 U micrococcal nuclease (Sigma) and  
165 incubation at 37 °C for 10 min in order to cleave DNA from the nucleus. The nuclease reaction  
166 was stopped by adding 5  $\mu\text{L}$  EDTA (0.5 M). Supernatant containing cleaved DNA was quantified  
167 using the QuantiFluor® dsDNA system (Promega, Madison, USA) in black 96-well plates  
168 (Thermo Fisher Scientific) using serially diluted lambda DNA as a standard. Measurement was  
169 carried out at 485 nm excitation/ 535 nm emission on VarioskanFlash (SkanIt Software 2.4.3 RE  
170 for Varioskan Flash).

171

#### 172 *Statistical analysis*

173 For data analysis, GraphPad Prism 7 (v. 7.03 h, GraphPad Software, Inc.) and  
174 VarioskanFlash (SkanIt Software 2.4.3 RE for Varioskan Flash) were used. The unpaired two-  
175 tailed *t* test was used. All data are presented as mean  $\pm$  SEM. Statistical significance was set  
176 \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  and NS = not significant.



177 **3. Results**

178 *Participant characteristics*

179 Fifty-one Ov<sup>+</sup>HBA<sup>-</sup> and twenty-two Ov<sup>+</sup>HBA<sup>+</sup> patients in this study were from Kalasin Province  
 180 (Table 1). Most of Ov<sup>+</sup>HBA<sup>-</sup> patients were female (60.78%), while most patients with HBAs were  
 181 male (81.82%). The average age of each group was comparable (51.25 ± 6.23 vs 51.14 ± 6.20, *p*  
 182 =0.680 (Table 1). Levels of *Ov* infection, as measured by eggs-per-gram (EPG) were also  
 183 comparable between the two groups (18.45 ± 20.53 vs 16.69 ± 14.85, *p*=0.634). All subjects were  
 184 under 60 years old.

185 **Table 1 Baseline characteristics of participants in this study**

Characteristics	Population (%)		<i>p</i> -Value
	Ov <sup>+</sup> HBA <sup>-</sup> (n=51)	Ov <sup>+</sup> HBA <sup>+</sup> (n=22)	
<b>Gender</b>			
Male	20 (39.22%)	18 (81.82%)	< 0.001
Female	31 (60.78%)	4 (18.18%)	
<b>Age</b>			
Years of age (mean ± SD)	51.25 ± 6.23	51.14 ± 6.20	0.680
<b>EPG</b>	18.45 ± 20.53	16.69 ± 14.85	0.634

186

187

188 *Ov* crude antigens induced NET production in neutrophils from *Ov*-free individuals without HBAs

189 To study the effects of different doses of *Ov* crude antigens on NET release, we stained  
190 isolated neutrophils from *Ov*-free individual with DAPI. Using confocal microscopy, we observed  
191 that human neutrophils release NETs (Fig.1) when treated with any of the *Ov* crude antigen  
192 concentrations tested (2 µg/mL protein (Fig.1g), 5 µg/mL (Fig.1-k), 10 µg/mL (Fig.1-o), 15 µg/mL  
193 (Fig.1-s) and 20 µg/mL (Fig.1-w). As a negative control, we used only culture media instead of  
194 *Ov* antigens and used it for a cut-off to determine NET release (Fig.1c). On the other hand, as a  
195 positive control, PMA-treated neutrophils released NETs as expected. Of note, the amount of NET  
196 released increased in a dose-dependent manner and peaked at 10 µg/mL of *Ov* antigens before  
197 falling at higher concentrations of *Ov* antigens (15 µg/mL and 20 µg/mL) (Fig. 2B). However, the  
198 release of NETs at all *Ov*-antigen concentrations was higher than in untreated controls.

199 To test whether neutrophils that released NETs also underwent degranulation, we stained  
200 neutrophils with antibodies against MPO and NE and observed spatial distribution under a  
201 confocal microscope. We found that neutrophils when treated with *Ov* crude antigens release NETs  
202 together with MPO and NE in a dose-dependent manner. We found MPO and NETs starting at 5  
203 µg/mL of *Ov* antigen (Fig.1-l), and of NE and NETs starting at 2 µg/mL *Ov* antigen (Fig. 1-h).  
204 Interestingly, we observed that all three (MPO, NE and NETs) only when neutrophils were treated  
205 with *Ov* crude antigen at concentrations of 15 µg/mL and 20 µg/mL. ~~Together, our results indicate~~  
206 ~~that neutrophils from *Ov*-free individuals can release NETs together with the granular proteins~~  
207 ~~MPO and NE in response to *Ov* crude antigens.~~

208

209

210 *NETs are formed in patients with hepatobiliary abnormalities (HBA+) and Ov infection*

211 Because NETs are involved with pathology and severity of parasitic diseases such as  
212 malaria (Knackstedt et al., 2019), we sought to investigate if this also true for *Ov*-induced HBAs.  
213 We compared the quantities of NET released from neutrophils of individuals without HBAs who  
214 were positive for *Ov* eggs in feces ( $Ov^+HBA^-$ ) with quantities from the *Ov* egg-positive and HBA-  
215 positive group ( $Ov^+HBA^+$ ). We found elevated levels of NETs in the latter group (Fig.2).  
216 Interestingly, when these neutrophils were challenged with *Ov* crude antigens, we observed lower  
217 NET release in both groups regardless of their HBA status.

218

## 219 **Discussion**

220 Neutrophils release NETs upon encounter with large pathogens that usually cannot be  
221 phagocytosed (Branzk et al., 2014). In the case of extracellular parasites, especially when the  
222 infection is chronic and the infectious organism well evolved with the host, release of NETs might  
223 be an inappropriate response, causing bystander tissue damage and contributing to  
224 immunopathology. In this work, we decided to test whether *Ov* crude antigens can induce NET  
225 formation and release in *Ov*-free individuals compared to patients infected with the parasite with  
226 or without hepatobiliary abnormalities (HBAs). Our study shows for the first time that *Ov* crude  
227 antigens can induce NETs *ex-vivo* in a dose-dependent manner from neutrophils isolated from  
228 three *Ov*-free individuals. Intriguingly, when we measured NETs from neutrophils isolated from  
229 *Ov*-infected patients, we found increased spontaneous NET release in patients with HBAs.  
230 Interestingly, treatment with *Ov* crude antigens lowered the level of NETs in patients with active  
231 *Ov* infection regardless of HBA status.

232

233           There is compelling evidence that neutrophils form NETs in response to helminth and  
234 protist parasites: *Ostertagia ostertagi* (Mendez et al., 2018), *Haemonchus contortus* (Munoz-Caro  
235 et al., 2015), *Neospora caninum* (Villagra-Blanco et al., 2017), *Eimeria bovis* (Behrendt et al.,  
236 2010) and recently *Fasciola hepatica* (Peixoto et al., 2021). In line with these studies, our results  
237 show that human neutrophils release NETs in a dose-dependent manner after encounter with crude  
238 *Ov* antigens. We observed NETs in response to a very low concentration of *Ov* crude antigens,  
239 suggesting this response may be possible *in vivo*, where the actual abundance of parasite antigen  
240 can be quite low at the start of acute infection. Although it is unclear whether neutrophils are  
241 recruited to the site of *Ov* infection in response to antigens released by the fluke, several studies  
242 have reported a rapid recruitment of neutrophils to the site of infection by *Strongyloides*  
243 *sterocoralis* (Galioto et al., 2006) and *Heligmosomoides polygyrus* (Anthony et al., 2006). It is  
244 possible that such a recruitment may be prompted by tissue injury caused by parasite larvae and  
245 also by parasite-derived chemotactic factors.

246           *Ov* crude antigens had been reported to activate bile-duct epithelial cells via TLR2  
247 (Yongvanit et al., 2012). Given that ligation of TLR2 results in vital NETs, in which neutrophils  
248 are still viable and can perform other functions such as secretion of ROS, it is possible that *Ov*  
249 crude antigens may stimulate a similar pathway to release NETs. Previously, we showed that  
250 enhanced neutrophil functions, including production of ROS, were associated with HBAs (Salao  
251 et al., 2020). Thus, NETs observed in this study further confirm our hypothesis on the association  
252 of enhanced innate immunity with development of cholangiocarcinoma (Edwards et al., 2018).

253           NETs cause tissue injury in liver diseases (Hilscher and Shah, 2020) such as alcohol-  
254 associated liver diseases and portal hypertension and cancer. NE from NETs is associated with  
255 matrix metalloproteinase-9 (MMP-9) for activation of dormant cancer cells (Albregues et al.,

256 2018). Likewise, several studies report pro-tumorigenic role of NETs in different cancers (Bravo-  
257 Fernandez et al., 1985, Boone et al., 2015). Interestingly, we detected spontaneous release of NETs  
258 in patients with HBAs in both *Ov* crude antigen-untreated and -treated groups. These results imply  
259 that NETs are correlated with HBAs, as a result of wound healing following tissue damage.

260 This study has some limitations. First, the NETs we observed only came from *ex vivo*  
261 experiments that may not represent what happens *in vivo*. Second, although it is possible that  
262 neutrophils may directly interact with live *Ov* during the early phase of infection, our study did not  
263 investigate such an interaction. Third, our subjects were all from *Ov*-endemic areas. Past, repeated  
264 or chronic infection with *Ov* may have interfered and caused bias to our results. A study of the  
265 effects of acute and chronic infection on NET release and formation of HBAs would be  
266 worthwhile. Other future studies could include how NETs may form *in vivo* and their effect on  
267 cancer development.

268

## 269 **Conclusion**

270 We investigated whether human neutrophils could form NETs in response to *Ov* crude  
271 antigens. We found that NETs were released at all tested concentrations of *Ov* crude antigens in a  
272 dose-dependent fashion, and these NETs may be harmful to both the parasite and host. We propose  
273 that in the case of acute *Ov* infection, when concentration of *Ov* crude antigens is relatively low,  
274 neutrophils could form NETs. However, when this infection becomes chronic, manifesting as  
275 HBAs, these levels of NETs were reduced when neutrophils were treated with *Ov* crude antigens.  
276 Excessive production of proinflammatory mediators from these NETs might have an effect on the

277 parasites, but might also lead to excessive injury of surrounding tissues and hence result in  
278 hepatobiliary abnormalities.

279

## 280 **Funding**

281 This research was supported by The Office of National Higher Education Science Research and  
282 Innovation Policy Council (NXPO) through Program Management Unit for Human Resources &  
283 Institutional Development, Research and Innovation (PMU-B) (Re-submit, Year 2563). The work  
284 was granted by Faculty of Medicine, Khon Kaen University, Thailand (Grant Number IN62337).  
285 KW was funded by a scholarship from Cholangiocarcinoma Research Institute (Grant Number  
286 008/2560).

287

## 288 **Acknowledgements**

289 The author thanks to Cholangiocarcinoma Research Institute for awarding a scholarship to KW.  
290 We also would like to thank Professor David Blair for his English proofreading of this paper.

291

## 292 **Author contributions**

293 KW, BS, SWE and KS conceived and designed the study. KW, CC and WD conducted  
294 experiments. KW, SWE and KS wrote the first draft of the manuscript. KW, SC, KF, SS, ST, BS,  
295 SWE and KS edited and finalized the manuscript.

296

## 297 **Conflict of interest statement**

298 The authors declare no conflict of interest.

299 **References**

300 ALBRENGUES, J., SHIELDS, M. A., NG, D., PARK, C. G., AMBRICO, A., POINDEXTER, M. E., UPADHYAY, P.,  
301 UYEMINAMI, D. L., POMMIER, A., KUTTNER, V., BRUZAS, E., MAIORINO, L., BAUTISTA, C.,  
302 CARMONA, E. M., GIMOTTY, P. A., FEARON, D. T., CHANG, K., LYONS, S. K., PINKERTON, K. E.,  
303 TROTMAN, L. C., GOLDBERG, M. S., YEH, J. T. & EGEGLAD, M. 2018. Neutrophil extracellular traps  
304 produced during inflammation awaken dormant cancer cells in mice. *Science*, 361.  
305 ANTHONY, R. M., URBAN, J. F., JR., ALEM, F., HAMED, H. A., ROZO, C. T., BOUCHER, J. L., VAN ROOIJEN,  
306 N. & GAUSE, W. C. 2006. Memory T(H)2 cells induce alternatively activated macrophages to  
307 mediate protection against nematode parasites. *Nat Med*, 12, 955-60.  
308 BABATUNDE, K. A. & ADENUGA, O. F. 2022. Neutrophils in malaria: A double-edged sword role. *Front*  
309 *Immunol*, 13, 922377.  
310 BEHRENDT, J. H., RUIZ, A., ZAHNER, H., TAUBERT, A. & HERMOSILLA, C. 2010. Neutrophil extracellular  
311 trap formation as innate immune reactions against the apicomplexan parasite *Eimeria bovis*. *Vet*  
312 *Immunol Immunopathol*, 133, 1-8.  
313 BOONE, B. A., ORLICHENKO, L., SCHAPIRO, N. E., LOUGHRAN, P., GIANFRATE, G. C., ELLIS, J. T., SINGHI, A.  
314 D., KANG, R., TANG, D., LOTZE, M. T. & ZEH, H. J. 2015. The receptor for advanced glycation end  
315 products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer.  
316 *Cancer Gene Ther*, 22, 326-34.  
317 BORTHWICK, L. A., WYNN, T. A. & FISHER, A. J. 2013. Cytokine mediated tissue fibrosis. *Biochim Biophys*  
318 *Acta*, 1832, 1049-60.  
319 BRANZK, N., LUBOJEMSKA, A., HARDISON, S. E., WANG, Q., GUTIERREZ, M. G., BROWN, G. D. &  
320 PAPAYANNOPOULOS, V. 2014. Neutrophils sense microbe size and selectively release neutrophil  
321 extracellular traps in response to large pathogens. *Nat Immunol*, 15, 1017-25.  
322 BRAVO-FERNANDEZ, E. F., TORRES, E. A. & ZAITER, J. 1985. Acute colonic pseudo-obstruction (Ogilvie's  
323 syndrome): a case report showing the benefit of colonoscopy. *Bol Asoc Med P R*, 77, 234-6.  
324 EDWARDS, S. W., SPOFFORD, E. M., PRICE, C., WRIGHT, H. L., SALAO, K., SUTTIPRAPA, S. & SRIPA, B.  
325 2018. Opisthorchiasis-Induced Cholangiocarcinoma: How Innate Immunity May Cause Cancer.  
326 *Adv Parasitol*, 101, 149-176.  
327 ELKINS, D. B., MAIRIANG, E., SITHITHAWORN, P., MAIRIANG, P., CHAIYAKUM, J., CHAMADOL, N.,  
328 LOAPAIBOON, V. & HASWELL-ELKINS, M. R. 1996. Cross-sectional patterns of hepatobiliary  
329 abnormalities and possible precursor conditions of cholangiocarcinoma associated with  
330 *Opisthorchis viverrini* infection in humans. *Am J Trop Med Hyg*, 55, 295-301.  
331 FUCHS, T. A., ABED, U., GOOSMANN, C., HURWITZ, R., SCHULZE, I., WAHN, V., WEINRAUCH, Y.,  
332 BRINKMANN, V. & ZYCHLINSKY, A. 2007. Novel cell death program leads to neutrophil  
333 extracellular traps. *J Cell Biol*, 176, 231-41.  
334 GALIOTO, A. M., HESS, J. A., NOLAN, T. J., SCHAD, G. A., LEE, J. J. & ABRAHAM, D. 2006. Role of  
335 eosinophils and neutrophils in innate and adaptive protective immunity to larval *strongyloides*  
336 *stercoralis* in mice. *Infect Immun*, 74, 5730-8.  
337 HILSCHER, M. B. & SHAH, V. H. 2020. Neutrophil Extracellular Traps and Liver Disease. *Semin Liver Dis*,  
338 40, 171-179.  
339 KHAMWONG, M., PHANTHANAWIBOON, S., SALAO, K. & CHAREONSUDJAI, S. 2022. *Burkholderia*  
340 *pseudomallei* biofilm phenotypes confined but surviving in neutrophil extracellular traps of  
341 varying appearance. *Front Immunol*, 13, 926788.  
342 KNACKSTEDT, S. L., GEORGIADOU, A., APEL, F., ABU-ABED, U., MOXON, C. A., CUNNINGTON, A. J.,  
343 RAUPACH, B., CUNNINGHAM, D., LANGHORNE, J., KRUGER, R., BARRERA, V., HARDING, S. P.,  
344 BERG, A., PATEL, S., OTTERDAL, K., MORDMULLER, B., SCHWARZER, E., BRINKMANN, V.,

345 ZYCHLINSKY, A. & AMULIC, B. 2019. Neutrophil extracellular traps drive inflammatory  
346 pathogenesis in malaria. *Sci Immunol*, 4.

347 MAIRIANG, E., CHAIYAKUM, J., CHAMADOL, N., LAOPAIBOON, V., SRINAKARIN, J., KUNPITAYA, J.,  
348 SRIAMPORN, S., SUWANRUNGRUANG, K. & VATANASAPT, V. 2006. Ultrasound screening for  
349 *Opisthorchis viverrini*-associated cholangiocarcinomas: experience in an endemic area. *Asian Pac*  
350 *J Cancer Prev*, 7, 431-3.

351 MAIRIANG, E., ELKINS, D. B., MAIRIANG, P., CHAIYAKUM, J., CHAMADOL, N., LOAPAIBOON, V., POSRI, S.,  
352 SITHITHAWORN, P. & HASWELL-ELKINS, M. 1992. Relationship between intensity of *Opisthorchis*  
353 *viverrini* infection and hepatobiliary disease detected by ultrasonography. *J Gastroenterol*  
354 *Hepatol*, 7, 17-21.

355 MAIRIANG, E., LAHA, T., BETHONY, J. M., THINKHAMROP, B., KAEWKES, S., SITHITHAWORN, P., TESANA,  
356 S., LOUKAS, A., BRINDLEY, P. J. & SRIPA, B. 2012. Ultrasonography assessment of hepatobiliary  
357 abnormalities in 3359 subjects with *Opisthorchis viverrini* infection in endemic areas of Thailand.  
358 *Parasitol Int*, 61, 208-11.

359 MAIRIANG, E. & MAIRIANG, P. 2003. Clinical manifestation of opisthorchiasis and treatment. *Acta Trop*,  
360 88, 221-7.

361 MENDEZ, J., SUN, D., TUO, W. & XIAO, Z. 2018. Bovine neutrophils form extracellular traps in response  
362 to the gastrointestinal parasite *Ostertagia ostertagi*. *Sci Rep*, 8, 17598.

363 MUNOZ-CARO, T., RUBIO, R. M., SILVA, L. M., MAGDOWSKI, G., GARTNER, U., MCNEILLY, T. N., TAUBERT,  
364 A. & HERMOSILLA, C. 2015. Leucocyte-derived extracellular trap formation significantly  
365 contributes to *Haemonchus contortus* larval entrapment. *Parasit Vectors*, 8, 607.

366 NATHAN, C. 2006. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol*, 6, 173-82.

367 PEIXOTO, R., SILVA, L. M. R., LOPEZ-OSORIO, S., ZHOU, E., GARTNER, U., CONEJEROS, I., TAUBERT, A. &  
368 HERMOSILLA, C. 2021. *Fasciola hepatica* induces weak NETosis and low production of intra- and  
369 extracellular ROS in exposed bovine polymorphonuclear neutrophils. *Dev Comp Immunol*, 114,  
370 103787.

371 SALAO, K., SPOFFORD, E. M., PRICE, C., MAIRIANG, E., SUTTIPRAPA, S., WRIGHT, H. L., SRIPA, B. &  
372 EDWARDS, S. W. 2020. Enhanced neutrophil functions during *Opisthorchis viverrini* infections  
373 and correlation with advanced periductal fibrosis. *Int J Parasitol*, 50, 145-152.

374 SMOUT, M. J., SRIPA, B., LAHA, T., MULVENNA, J., GASSER, R. B., YOUNG, N. D., BETHONY, J. M.,  
375 BRINDLEY, P. J. & LOUKAS, A. 2011. Infection with the carcinogenic human liver fluke,  
376 *Opisthorchis viverrini*. *Mol Biosyst*, 7, 1367-75.

377 SRIPA, B., BETHONY, J. M., SITHITHAWORN, P., KAEWKES, S., MAIRIANG, E., LOUKAS, A., MULVENNA, J.,  
378 LAHA, T., HOTEZ, P. J. & BRINDLEY, P. J. 2011. Opisthorchiasis and *Opisthorchis*-associated  
379 cholangiocarcinoma in Thailand and Laos. *Acta Trop*, 120 Suppl 1, S158-68.

380 SRIPA, B., BRINDLEY, P. J., MULVENNA, J., LAHA, T., SMOUT, M. J., MAIRIANG, E., BETHONY, J. M. &  
381 LOUKAS, A. 2012. The tumorigenic liver fluke *Opisthorchis viverrini*--multiple pathways to  
382 cancer. *Trends Parasitol*, 28, 395-407.

383 SRIPA, B., KAEWKES, S., SITHITHAWORN, P., MAIRIANG, E., LAHA, T., SMOUT, M., PAIROJKUL, C.,  
384 BHUDHISAWASDI, V., TESANA, S., THINKAMROP, B., BETHONY, J. M., LOUKAS, A. & BRINDLEY, P.  
385 J. 2007. Liver fluke induces cholangiocarcinoma. *PLoS Med*, 4, e201.

386 SRIPA, B., MAIRIANG, E., THINKHAMROP, B., LAHA, T., KAEWKES, S., SITHITHAWORN, P., TESSANA, S.,  
387 LOUKAS, A., BRINDLEY, P. J. & BETHONY, J. M. 2009. Advanced periductal fibrosis from infection  
388 with the carcinogenic human liver fluke *Opisthorchis viverrini* correlates with elevated levels of  
389 interleukin-6. *Hepatology*, 50, 1273-81.

390 THANABALASURIAR, A., SCOTT, B. N. V., PEISELER, M., WILLSON, M. E., ZENG, Z., WARRENER, P., KELLER,  
391 A. E., SUREWAARD, B. G. J., DOZIER, E. A., KORHONEN, J. T., CHENG, L. I., GADJEVA, M., STOVER,  
392 C. K., DIGIANDOMENICO, A. & KUBES, P. 2019. Neutrophil Extracellular Traps Confine



393 *Pseudomonas aeruginosa* Ocular Biofilms and Restrict Brain Invasion. *Cell Host Microbe*, 25, 526-  
394 536 e4.  
395 VILLAGRA-BLANCO, R., SILVA, L. M. R., MUNOZ-CARO, T., YANG, Z., LI, J., GARTNER, U., TAUBERT, A.,  
396 ZHANG, X. & HERMOSILLA, C. 2017. Bovine Polymorphonuclear Neutrophils Cast Neutrophil  
397 Extracellular Traps against the Abortive Parasite *Neospora caninum*. *Front Immunol*, 8, 606.  
398 WONKCHALEE, O., BOONMARS, T., KAEWKES, S., CHAMGRAMOL, Y., AROMDEE, C., WU, Z., JUASOOK, A.,  
399 SUDSARN, P., BOONJARASPINYO, S. & PAIROJKUL, C. 2012. Comparative studies on animal  
400 models for *Opisthorchis viverrini* infection: host interaction through susceptibility and pathology.  
401 *Parasitol Res*, 110, 1213-23.  
402 WYNN, T. A. & RAMALINGAM, T. R. 2012. Mechanisms of fibrosis: therapeutic translation for fibrotic  
403 disease. *Nat Med*, 18, 1028-40.  
404 YONGVANIT, P., THANAN, R., PINLAOR, S., SITHITHAWORN, P., LOILOME, W., NAMWAT, N., TECHASEN,  
405 A. & DECHAKHAMPHU, S. 2012. Increased expression of TLR-2, COX-2, and SOD-2 genes in the  
406 peripheral blood leukocytes of opisthorchiasis patients induced by *Opisthorchis viverrini* antigen.  
407 *Parasitol Res*, 110, 1969-77.

408

409


#### 410 **Legends for Figures**

#### 411 **Fig. 1 *Ov* crude antigen induced NET production in neutrophils from *Ov*-free individuals.**


412  $1 \times 10^5$  of neutrophils from *Ov*-free and non-HBA individual were confronted with *Ov* crude  
413 antigens at final protein concentrations of 2 (e-h), 5 (i-l), 10 (m-p), 15 (q-t) and 20 (u-x)  $\mu\text{g/mL}$   
414 and PMA concentration 1  $\text{mg/mL}$  (z-b1) for 3 h at 37 °C and 5%  $\text{CO}_2$ . For confocal microscopy,  
415 the cells were stained with MPO (red), NE (green) and DAPI (blue) (representative image from 3  
416 *Ov*-free individual (A). Quantification of NETs was performed after incubation of untreated  
417 controls and *Ov* crude antigens (n=3) (B). All experiments were performed in duplicate. Area of  
418 NETs was measured using ImageJ software. Bars represent mean  $\pm$  SEM. All data were analyzed  
419 by *t* test; \* $P < 0.05$ , \*\* $P < 0.001$  and \*\*\*\* $P < 0.0001$ . Scale bar 20  $\mu\text{m}$ .

#### 420 **Fig. 2 NETs were elevated in *Ov*-infected patients with hepatobiliary abnormalities**


421 Neutrophils from *Ov*-infected patients with or without HBA were treated with *Ov* crude antigens  
422 (10  $\mu\text{g/mL}$ ) and NETs were measured using spectral cytometry. Data are analyzed as mean $\pm$ SEM;  
423 \* $P < 0.05$  using *t* tests (n=51 for  $\text{Ov}^+\text{HBA}^-$ , n=22 for  $\text{Ov}^+\text{HBA}^+$ )



**B**



**Fig. 1** *Ov* crude antigen induced NET production in neutrophils from *Ov*-free individuals.



**Fig. 2** NETs were elevated in *Ov*-infected patients with hepatobiliary abnormalities